Australia Spinal Surgery Devices Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia spinal surgery devices market is shifting from price-led supply of standard fusion hardware towards technology-led procedures. Private hospitals still generate most implant volume, but robotic guidance, motion preservation and registry-based oversight are changing how devices are chosen and justified.

Three forces are shaping the market: benefit reductions under the Prescribed List reforms, which have squeezed implant margins; a shortage of neurosurgical capacity in public systems; and a stream of imported disc and fusion devices entering through new distributor arrangements.

In April 2025, the University of Melbourne secured an AUD 7 million Medical Research Future Fund grant to build the Australian Spine Registry into a national clinical quality registry. In October 2025, Johnson & Johnson announced plans to separate its orthopaedics business as DePuy Synthes.

Key Market Trends and Insights

• Reform Concentrated on Spine: The final evaluation of the Prescribed List reforms, published in June 2026, found that over half of the 5,006 items with reduced benefits sat in the orthopaedic and spinal categories.
• Advanced Implants Harder to Source: The same June 2026 evaluation recorded private hospitals struggling to obtain newer spinal implants, while the benefit for fusion cages remained more than five times a French benchmark price.
• Public Capacity Is Stretched: In October 2025, WA Health said its 10 neurosurgeons performed 1,019 elective spinal procedures in 12 months, while doctors warned that shortages were delaying surgery for spinal patients.
• Willingness to Operate: A University of South Australia study released in December 2025 found 24% of privately insured adults would consider spinal surgery within five years, shaped strongly by beliefs about pain.

Australia Spinal Surgery Devices Market Size and Forecast

The market is moving from commodity pedicle screws and cages towards platforms that combine implants with planning, navigation and robotic guidance. Fixation implants remain the largest category, while navigation and robotic systems advance fastest as private hospitals invest in precision. Lumbar degenerative surgery anchors volume, cervical procedures grow more quickly, and day surgery centres gain share. New South Wales is the largest state and Queensland grows quickest. Registry oversight, reimbursement discipline and surgeon capacity will shape a steady multi-year outlook.

Key Takeaways: Australia Spinal Surgery Devices Market

Reimbursement Discipline Meets Rising Procedure Need

Revenue is on course to expand by about 66% across the decade, from AUD 620.00 million in 2025 to AUD 1,029.32 million in 2035 at a 5.2% CAGR. Ageing, chronic back pain and private cover support volume while benefit controls cap price growth.

Precision Technology and Cervical Surgery Lead Growth

Fixation implants remain the largest category, but navigation and robotic systems grow at an estimated 7.6% CAGR and cervical procedures at an estimated 6.5% CAGR through 2035. Day surgery centres are expected to rise at 6.8% as lower-acuity cases move out of hospital wards.

DePuy Synthes Separation Reshapes a Major Supplier

Johnson & Johnson announced its intent to separate its orthopaedics business as DePuy Synthes in October 2025, creating a standalone supplier whose spine portfolio competes directly with Medtronic and Globus Medical in Australian theatres.

• Announced on 14 October 2025
• Completion targeted within 18 to 24 months
• Namal Nawana appointed Worldwide President

Australia Spinal Surgery Devices Market Report Summary

Key Insight

Reimbursement reform, an ageing population and surgeon capacity shape the outlook. Fixation hardware holds the revenue base, while robotics, navigation and cervical procedures supply the fastest growth.

Key Trends in the Australia Spinal Surgery Devices Market

The Australia spinal surgery devices market is being reshaped by reimbursement evaluation, new Prescribed List rules and shifting patient attitudes towards operating, while global suppliers expand international spine sales.

August 2026 - Globus Medical Reports Double-Digit International Spine Growth

• Globus Medical reported on 6 August 2026 second-quarter worldwide sales of USD 789.6 million, up 5.9%, with international spine sales up 14%.
• The company reaffirmed 2026 revenue guidance of USD 3.18 billion to USD 3.22 billion and raised its earnings per share outlook.
• Markets outside the United States, including Australia, are contributing faster growth than the home spine market.

July 2026 - Prescribed List Rules Take Effect for Devices and Human Tissue Products

• The Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 3) 2026 were registered on 22 June 2026 and commenced on 1 July 2026.
• They give effect to completed Prescribed List applications covering new, amended, expanded, compressed, deleted and transferred items.
• Sponsors of spinal implants must align billing codes and benefits with the updated list.

June 2026 - Final Evaluation Finds Spinal Items Dominated Benefit Reductions

• The Department of Health published its final evaluation of the Prescribed List reforms on 16 June 2026.
• Benefits fell for 5,006 items, and over half sat in the specialist orthopaedic or spinal categories.
• Some private hospitals said pricing constraints made newer or advanced spinal implants harder to source.

December 2025 - University of South Australia Study Probes Appetite for Spinal Surgery

• The study, released on 11 December 2025, surveyed 152 privately insured adults and found 24% would consider spinal surgery within five years.
• Negative pain beliefs strongly predicted willingness, and spinal fusion was described as costing up to AUD 46,000.
• Pain programs costing AUD 3,000 to AUD 8,000 were presented as an alternative, tempering elective demand.

Key Insight

Policy and reimbursement now move together with product supply. Benefit rules, evaluation findings and patient attitudes influence which implants hospitals buy, while global suppliers sustain international spine growth.

Recent Market Developments in the Australia Spinal Surgery Devices Market

Recent developments, presented from the most recent, show the Australia spinal surgery devices market moving from registry building and new device approvals to supplier restructuring and results.

June 2026 - Medtronic Reports Cranial and Spinal Technologies Revenue

• Medtronic reported on 3 June 2026 fourth-quarter and full-year results for the fiscal year ended 24 April 2026.
• Its Cranial and Spinal Technologies business generated USD 5.2 billion in revenue, up 5%.
• Chief executive Geoff Martha named the unit among the company's largest businesses.

October 2025 - Evolution Surgical Becomes Sole Australian Distributor of Spineway Discs

• Spineway announced on 22 October 2025 that Evolution Surgical would distribute its CP-ESP and LP-ESP disc prostheses in Australia from 25 October 2025.
• Evolution Surgical replaces Orthotech as distributor, which will help manage the transition.
• The disc prostheses extend the fusion device range of the Sydney-based supplier.

April 2025 - ASPIRE Wins Grant to Build the National Spine Registry

• The University of Melbourne announced on 4 April 2025 that ASPIRE secured a AUD 7 million Medical Research Future Fund device surveillance grant.
• Professor Peter Choong leads the project to monitor spinal implant safety and evaluate treatments across Australia.
• Partners include the Australian Orthopaedic Association, the Neurosurgical Society of Australia, the Spine Society of Australia and the Medical Technology Association of Australia.

March 2025 - Minuteman G5 and MOVE-C Gain Australian Clearance

• Spinal Simplicity announced on 11 March 2025 clearance of its Minuteman G5 interspinous fusion device in Australia and New Zealand.
• NGMedical announced on 19 March 2025 that the Therapeutic Goods Administration approved its MOVE-C cervical artificial disc, sold through Matrix Medical Innovations.
• Both launches widen minimally invasive and motion preservation choices.

Key Insight

Recent events show supply being broadened and restructured. New devices gain clearance and distributors change, while registry funding and supplier results point to sustained attention on spinal technology.

Australia Spinal Surgery Devices Industry Segmentation

The Expert Market Research’s report on the Australia Spinal Surgery Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Thoracolumbar Fixation Implants
• Interbody Fusion Devices
• Spinal Biologics and Bone Graft Substitutes
• Motion Preservation and Vertebral Augmentation Devices
• Navigation and Robotic Systems
• Others

Thoracolumbar Fixation Implants lead revenue, covering pedicle screws, rods and plates that benefit from Globus Medical's international spine momentum reported in August 2026. Interbody Fusion Devices follow, with Spinal Simplicity's Minuteman G5 cleared in March 2025. Spinal Biologics and Bone Graft Substitutes support fusion rates. Motion Preservation and Vertebral Augmentation Devices include NGMedical's MOVE-C disc, approved in March 2025. Navigation and Robotic Systems grow fastest at an estimated 7.6% CAGR through 2035. Others covers instruments, neuromonitoring accessories and spinal tools.

Market Breakup by Procedure Type

• Lumbar Degenerative Procedures
• Cervical Procedures
• Deformity and Scoliosis Correction
• Trauma and Tumour Reconstruction
• Others

Lumbar Degenerative Procedures lead volume, since one in six Australians live with chronic back pain according to a December 2025 University of South Australia release. Cervical Procedures grow fastest at an estimated 6.5% CAGR, helped by artificial disc approvals such as MOVE-C in March 2025. Deformity and Scoliosis Correction depends on specialist units and custom instrumentation. Trauma and Tumour Reconstruction follows emergency and cancer pathways, where neurosurgeon supply matters. Others covers revision surgery and minor decompression hardware.

Market Breakup by End User

• Private Hospitals
• Public Hospitals
• Day Surgery Centres and Specialist Clinics
• Others

Private Hospitals lead because implants are reimbursed through the Prescribed List, whose June 2026 evaluation said some hospitals found newer spinal implants harder to source. Public Hospitals face capacity limits, with WA Health reporting 1,019 elective spinal procedures from 10 neurosurgeons in October 2025. Day Surgery Centres and Specialist Clinics grow fastest at an estimated 6.8% CAGR, as short-stay cervical and minimally invasive cases move out of wards. Others covers veterans and compensation-scheme funded surgery.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates through the largest population and hospital base, growing at an estimated 4.9% CAGR through 2035, and hosts Sydney-based Evolution Surgical. Victoria follows at 5.0%, with the University of Melbourne leading the ASPIRE registry funded in April 2025. Queensland is the fastest-growing state at an estimated 5.9%, and the Neurosurgical Society of Australia met there from 13 to 15 August 2025. Western Australia grows at 5.6%, where doctors reported neurosurgeon shortages in October 2025. South Australia grows at 4.7%. Others covers Tasmania, the ACT and the Northern Territory at 5.3%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Spinal Surgery Devices Market

Competition combines global spine majors, specialist implant makers and local distributors. Entry barriers include Therapeutic Goods Administration registration, Prescribed List listing, surgeon training and the capital cost of navigation and robotic platforms.

Medtronic

Medtronic, headquartered in Dublin, Ireland, supplies spinal implants, biologics, navigation and robotic guidance through its Cranial and Spinal Technologies business, serving Australia via Medtronic Australasia. The unit generated USD 5.2 billion in revenue in the fiscal year ended 24 April 2026, up 5%, as reported on 3 June 2026. Medtronic expects total fiscal 2027 sales growth of 6.75% to 7.25%.

Globus Medical

Globus Medical, headquartered in Audubon, Pennsylvania, offers fixation, interbody and enabling technology, including the ExcelsiusGPS robot and Excelsius XR headset, which received US clearance in August 2025. It completed the acquisition of Nevro in April 2025. On 6 August 2026 it reported second-quarter sales of USD 789.6 million, with international spine up 14%.

DePuy Synthes

DePuy Synthes, based in Raynham, Massachusetts, is the orthopaedics unit of Johnson & Johnson MedTech and supplies spinal fixation and interbody systems used in Australian theatres. On 14 October 2025, Johnson & Johnson announced its intent to separate the business as a standalone company within 18 to 24 months, appointing Namal Nawana as Worldwide President.

Evolution Surgical

Evolution Surgical is a Sydney-headquartered orthopaedic device company that designs, manufactures and distributes spinal implants, including larger-sized implants and custom instrumentation. From 25 October 2025 it became sole Australian distributor of Spineway's CP-ESP and LP-ESP disc prostheses, replacing Orthotech, which broadened its fusion portfolio into motion preservation.

Other players operating in the Australia spinal surgery devices market include Stryker, Zimmer Biomet, Orthofix, NGMedical, and Spinal Simplicity, alongside distributors, private hospital groups, neurosurgery practices and registry partners supporting spinal implant supply across Australia.

Key Insight

Competition rests on clinical evidence, surgeon training, enabling technology and reliable supply rather than price alone. Global majors hold scale, while specialists compete through niche devices and local distribution.